While PARPi have demonstrated efficacy in BRCA-mutated, HER2-negative BC, their role in HER2-positive disease remains unclear because the clinical trials for the PARPi did not include HER2-positive BCs. The gene discussed is ERBB2; the disease is breast cancer.